Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $38.5 million.

  • CG Oncology's Total Non-Current Liabilities changed N/A to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.5 million, marking a year-over-year change of. This contributed to the annual value of $21.4 million for FY2024, which is 5142.09% up from last year.
  • CG Oncology's Total Non-Current Liabilities amounted to $38.5 million in Q3 2025.
  • CG Oncology's Total Non-Current Liabilities' 5-year high stood at $38.5 million during Q3 2025, with a 5-year trough of $14.1 million in Q4 2023.
  • In the last 3 years, CG Oncology's Total Non-Current Liabilities had a median value of $21.4 million in 2024 and averaged $24.7 million.
  • Examining YoY changes over the last 5 years, CG Oncology's Total Non-Current Liabilities showed a top increase of 5142.09% in 2024 and a maximum decrease of 5142.09% in 2024.
  • Over the past 3 years, CG Oncology's Total Non-Current Liabilities (Quarter) stood at $14.1 million in 2023, then skyrocketed by 51.42% to $21.4 million in 2024, then soared by 79.58% to $38.5 million in 2025.
  • Its last three reported values are $38.5 million in Q3 2025, $21.4 million for Q4 2024, and $14.1 million during Q4 2023.